These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 12384164)

  • 1. Age-related reference ranges for complexed prostate-specific antigen and complexed/total prostate-specific antigen ratio: results from East Texas Medical Center Cancer Institute screening campaign.
    Cheli CD; Levine RL; Cambetas DR; Kolker JD; Roberts SB
    Urology; 2002 Oct; 60(4 Suppl 1):53-9. PubMed ID: 12384164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
    Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
    Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer.
    Veltri RW; Miller MC; O'dowd GJ; Partin AW
    Urology; 2002 Oct; 60(4 Suppl 1):47-52. PubMed ID: 12384163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
    Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
    Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of age on complexed PSA levels in men with total PSA levels of up to 20 ng/mL.
    Berger AP; Cheli C; Levine R; Klocker H; Bartsch G; Horninger W
    Urology; 2003 Nov; 62(5):840-4. PubMed ID: 14624905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
    Miller MC; O'Dowd GJ; Partin AW; Veltri RW
    Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
    Partin AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD
    J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program.
    Barqawi AB; Golden BK; O'Donnell C; Brawer MK; Crawford ED
    Urology; 2005 Apr; 65(4):708-12. PubMed ID: 15833513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Urology; 2000 May; 55(5):700-4. PubMed ID: 10792084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can complexed prostate specific antigen enhance prostate cancer detection in Japanese men?
    Okihara K; Ukimura O; Nakamura T; Mizutani Y; Kawauchi A; Naya Y; Uchida M; Ogiwara T; Miki T
    Eur Urol; 2004 Jul; 46(1):57-64. PubMed ID: 15183548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
    Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
    Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
    Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
    Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening.
    Ellison L; Cheli CD; Bright S; Veltri RW; Partin AW
    Urology; 2002 Oct; 60(4 Suppl 1):42-6. PubMed ID: 12384162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL.
    Okegawa T; Kinjo M; Watanabe K; Noda H; Kato M; Miyata A; Murata A; Yoshii M; Nutahara K; Higashihara E
    BJU Int; 2000 Apr; 85(6):708-14. PubMed ID: 10759671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA.
    Parsons JK; Brawer MK; Cheli CD; Partin AW; Djavan R
    BJU Int; 2004 Jul; 94(1):47-50. PubMed ID: 15217429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
    Strittmatter F; Stieber P; Nagel D; Füllhase C; Walther S; Stief CG; Waidelich R
    Eur J Med Res; 2011 Oct; 16(10):445-50. PubMed ID: 22024423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complexed PSA improves prostate cancer detection: results from a multicenter Japanese clinical trial.
    Okihara K; Ukimura O; Nakamura T; Ushijima S; Mizutani Y; Kawauchi A; Naya Y; Kojima M; Miki T
    Urology; 2006 Feb; 67(2):328-32. PubMed ID: 16461082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The measurement of complexed prostate-specific antigen has a better performance than total prostate-specific antigen.
    Herrmann W; Stöckle M; Sand-Hill M; Hübner U; Herrmann M; Obeid R; Wullich B; Loch T; Geisel J
    Clin Chem Lab Med; 2004; 42(9):1051-7. PubMed ID: 15497472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.